The FDA asked for a $4.5 billion budget for fiscal 2013, up 17%, or $654 million, from this year. Industry user fees, including proposed fees for generics and biosimilars, would account for 45% of the budget and would fund 98% of the increase in spending.

Full Story:
DOTMed.com, Reuters

Related Summaries